Anticancer research · 2018
Pazopanib for Metastatic Renal Cell Carcinoma: A Registry-based Analysis of 426 Patients.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Poprach Alexandr, Fiala Ondrej, Chloupkova Renata, Melichar Bohuslav, Lakomy Radek, Petrakova Katarina, Zemanova Milada, Kopeckova Katerina, Slaby Ondrej, Studentova Hana, Kopecký Jindrich, Kiss Igor, Finek Jindrich, Dusek Ladislav, Buchler Tomas
Аннотация
BACKGROUND: Pazopanib is approved for the first-line treatment of patients with metastatic renal cell carcinoma (mRCC). The present study was a retrospective registry-based analysis of 426 patients with mRCC treated with pazopanib as first-line targeted therapy.
PATIENTS AND METHODS: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed.
RESULTS: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients.
CONCLUSION: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
PATIENTS AND METHODS: The data were obtained from the Renal Cell Carcinoma Information system registry. Patient baseline parameters, treatment course and outcomes, and toxicity were analysed.
RESULTS: Median progression-free and overall survival were 12.9 (95% confidence interval(CI)=11.0-14.8) months and 33.2 (95% CI=29.9-36.4) months, respectively. Overall response rate and disease control rate were 25.1% and 57.4%, respectively. Adverse events led to discontinuation of treatment in 37 (12.1%) patients.
CONCLUSION: The results confirm that pazopanib is an effective and safe first-line targeted treatment in patients with mRCC. Both the International mRCC Database Consortium and the Memorial Sloan Kettering models were valid predictors of prognosis and nephrectomy was associated with improved survival.
Предметные рубрики MeSH
AdultAgedAged, 80 and overAngiogenesis InhibitorsCarcinoma, Renal CellCzech RepublicDatabases, FactualDisease-Free SurvivalFemaleHumansIndazolesIndolesKidney NeoplasmsMaleMiddle AgedNephrectomyProto-Oncogene Proteins c-kitPyrimidinesPyrrolesReceptors, Platelet-Derived Growth FactorReceptors, Vascular Endothelial Growth FactorRegistriesRetrospective StudiesSulfonamidesSunitinibTreatment Outcome